node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
ADIRF | AGAP5 | ENSP00000361083 | ENSP00000363207 | Adipogenesis regulatory factor; Plays a role in fat cell development; promotes adipogenic differentiation and stimulates transcription initiation of master adipogenesis factors like PPARG and CEBPA at early stages of preadipocyte differentiation. Its overexpression confers resistance to the anticancer chemotherapeutic drug cisplatin | Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 5; Putative GTPase-activating protein; Ankyrin repeat domain containing | 0.473 |
ADIRF | ARHGEF39 | ENSP00000361083 | ENSP00000367638 | Adipogenesis regulatory factor; Plays a role in fat cell development; promotes adipogenic differentiation and stimulates transcription initiation of master adipogenesis factors like PPARG and CEBPA at early stages of preadipocyte differentiation. Its overexpression confers resistance to the anticancer chemotherapeutic drug cisplatin | Rho guanine nucleotide exchange factor 39; Promotes cell proliferation | 0.511 |
ADIRF | BCL2L13 | ENSP00000361083 | ENSP00000480836 | Adipogenesis regulatory factor; Plays a role in fat cell development; promotes adipogenic differentiation and stimulates transcription initiation of master adipogenesis factors like PPARG and CEBPA at early stages of preadipocyte differentiation. Its overexpression confers resistance to the anticancer chemotherapeutic drug cisplatin | Bcl-2-like protein 13; May promote the activation of caspase-3 and apoptosis; BCL2 family | 0.461 |
ADIRF | FAM25A | ENSP00000361083 | ENSP00000342790 | Adipogenesis regulatory factor; Plays a role in fat cell development; promotes adipogenic differentiation and stimulates transcription initiation of master adipogenesis factors like PPARG and CEBPA at early stages of preadipocyte differentiation. Its overexpression confers resistance to the anticancer chemotherapeutic drug cisplatin | Family with sequence similarity 25 member A; Belongs to the FAM25 family | 0.653 |
ADIRF | FAM25HP | ENSP00000361083 | ENSP00000485370 | Adipogenesis regulatory factor; Plays a role in fat cell development; promotes adipogenic differentiation and stimulates transcription initiation of master adipogenesis factors like PPARG and CEBPA at early stages of preadipocyte differentiation. Its overexpression confers resistance to the anticancer chemotherapeutic drug cisplatin | Protein FAM25A; Family with sequence similarity 25, member H pseudogene; Belongs to the FAM25 family | 0.595 |
ADIRF | IL18 | ENSP00000361083 | ENSP00000280357 | Adipogenesis regulatory factor; Plays a role in fat cell development; promotes adipogenic differentiation and stimulates transcription initiation of master adipogenesis factors like PPARG and CEBPA at early stages of preadipocyte differentiation. Its overexpression confers resistance to the anticancer chemotherapeutic drug cisplatin | Interleukin-18; Augments natural killer cell activity in spleen cells and stimulates interferon gamma production in T-helper type I cells; Belongs to the IL-1 family | 0.552 |
ADIRF | MMRN2 | ENSP00000361083 | ENSP00000361097 | Adipogenesis regulatory factor; Plays a role in fat cell development; promotes adipogenic differentiation and stimulates transcription initiation of master adipogenesis factors like PPARG and CEBPA at early stages of preadipocyte differentiation. Its overexpression confers resistance to the anticancer chemotherapeutic drug cisplatin | Multimerin-2; Inhibits endothelial cells motility and acts as a negative regulator of angiogenesis; it downregulates KDR activation by binding VEGFA; EMI domain containing | 0.503 |
ADIRF | PPARG | ENSP00000361083 | ENSP00000287820 | Adipogenesis regulatory factor; Plays a role in fat cell development; promotes adipogenic differentiation and stimulates transcription initiation of master adipogenesis factors like PPARG and CEBPA at early stages of preadipocyte differentiation. Its overexpression confers resistance to the anticancer chemotherapeutic drug cisplatin | Peroxisome proliferator-activated receptor gamma; Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut ho [...] | 0.904 |
ADIRF | TMCO4 | ENSP00000361083 | ENSP00000294543 | Adipogenesis regulatory factor; Plays a role in fat cell development; promotes adipogenic differentiation and stimulates transcription initiation of master adipogenesis factors like PPARG and CEBPA at early stages of preadipocyte differentiation. Its overexpression confers resistance to the anticancer chemotherapeutic drug cisplatin | Transmembrane and coiled-coil domains 4; Belongs to the TMCO4 family | 0.486 |
ADIRF | TMEM256 | ENSP00000361083 | ENSP00000301939 | Adipogenesis regulatory factor; Plays a role in fat cell development; promotes adipogenic differentiation and stimulates transcription initiation of master adipogenesis factors like PPARG and CEBPA at early stages of preadipocyte differentiation. Its overexpression confers resistance to the anticancer chemotherapeutic drug cisplatin | Transmembrane protein 256 | 0.491 |
AGAP5 | ADIRF | ENSP00000363207 | ENSP00000361083 | Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 5; Putative GTPase-activating protein; Ankyrin repeat domain containing | Adipogenesis regulatory factor; Plays a role in fat cell development; promotes adipogenic differentiation and stimulates transcription initiation of master adipogenesis factors like PPARG and CEBPA at early stages of preadipocyte differentiation. Its overexpression confers resistance to the anticancer chemotherapeutic drug cisplatin | 0.473 |
AGAP5 | FAM25A | ENSP00000363207 | ENSP00000342790 | Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 5; Putative GTPase-activating protein; Ankyrin repeat domain containing | Family with sequence similarity 25 member A; Belongs to the FAM25 family | 0.653 |
AGAP5 | FAM25HP | ENSP00000363207 | ENSP00000485370 | Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 5; Putative GTPase-activating protein; Ankyrin repeat domain containing | Protein FAM25A; Family with sequence similarity 25, member H pseudogene; Belongs to the FAM25 family | 0.571 |
AGAP5 | MMRN2 | ENSP00000363207 | ENSP00000361097 | Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 5; Putative GTPase-activating protein; Ankyrin repeat domain containing | Multimerin-2; Inhibits endothelial cells motility and acts as a negative regulator of angiogenesis; it downregulates KDR activation by binding VEGFA; EMI domain containing | 0.541 |
ARHGEF39 | ADIRF | ENSP00000367638 | ENSP00000361083 | Rho guanine nucleotide exchange factor 39; Promotes cell proliferation | Adipogenesis regulatory factor; Plays a role in fat cell development; promotes adipogenic differentiation and stimulates transcription initiation of master adipogenesis factors like PPARG and CEBPA at early stages of preadipocyte differentiation. Its overexpression confers resistance to the anticancer chemotherapeutic drug cisplatin | 0.511 |
BCL2L13 | ADIRF | ENSP00000480836 | ENSP00000361083 | Bcl-2-like protein 13; May promote the activation of caspase-3 and apoptosis; BCL2 family | Adipogenesis regulatory factor; Plays a role in fat cell development; promotes adipogenic differentiation and stimulates transcription initiation of master adipogenesis factors like PPARG and CEBPA at early stages of preadipocyte differentiation. Its overexpression confers resistance to the anticancer chemotherapeutic drug cisplatin | 0.461 |
FAM25A | ADIRF | ENSP00000342790 | ENSP00000361083 | Family with sequence similarity 25 member A; Belongs to the FAM25 family | Adipogenesis regulatory factor; Plays a role in fat cell development; promotes adipogenic differentiation and stimulates transcription initiation of master adipogenesis factors like PPARG and CEBPA at early stages of preadipocyte differentiation. Its overexpression confers resistance to the anticancer chemotherapeutic drug cisplatin | 0.653 |
FAM25A | AGAP5 | ENSP00000342790 | ENSP00000363207 | Family with sequence similarity 25 member A; Belongs to the FAM25 family | Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 5; Putative GTPase-activating protein; Ankyrin repeat domain containing | 0.653 |
FAM25A | MMRN2 | ENSP00000342790 | ENSP00000361097 | Family with sequence similarity 25 member A; Belongs to the FAM25 family | Multimerin-2; Inhibits endothelial cells motility and acts as a negative regulator of angiogenesis; it downregulates KDR activation by binding VEGFA; EMI domain containing | 0.674 |
FAM25HP | ADIRF | ENSP00000485370 | ENSP00000361083 | Protein FAM25A; Family with sequence similarity 25, member H pseudogene; Belongs to the FAM25 family | Adipogenesis regulatory factor; Plays a role in fat cell development; promotes adipogenic differentiation and stimulates transcription initiation of master adipogenesis factors like PPARG and CEBPA at early stages of preadipocyte differentiation. Its overexpression confers resistance to the anticancer chemotherapeutic drug cisplatin | 0.595 |